__NUXT_JSONP__("/drugs/Lutetium_Lu_177_Lilotomab-satetraxetan", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1453362-90-7",chebiId:b,chemicalFormula:b,definition:"A radioconjugate consisting of lilotomab, a murine immunoglobulin G1 (IgG1) antibody directed against the CD37 antigen, conjugated via the chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (p-SCN-Bn-DOTA) with potential antineoplastic activities. Upon administration of lutetium Lu 177 lilotomab-satetraxetan, the lilotomab moiety binds to CD37 expressed on certain tumor cells. Upon binding, lutetium Lu 177 lilotomab-satetraxetan delivers a cytotoxic dose of beta radiation to CD37-expressing cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell lymphomas.",fdaUniiCode:"054ZP16K2Q",identifier:"C162565",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129819","C1511"],synonyms:["177Lu Lilotomab Satetraxetan","177Lu-Lilotomab-satetraxetan","Betalutin","LILOTOMAB SATETRAXETAN LUTETIUM LU-177",c,"Lutetium Lu-177 Lilotomab Satetraxetan","Lutetium Lu-177 Lilotomab-satetraxetan"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLutetium_Lu_177_Lilotomab-satetraxetan",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Lutetium_Lu_177_Lilotomab-satetraxetan","","Lutetium Lu 177 Lilotomab-satetraxetan","2021-10-30T13:35:26.643Z")));